Company news

GlucoTrack, Inc. news in 2026

GlucoTrack, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Glucotrack, Inc. Announces Reverse Stock Split

October 22, 2026

Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications

October 14, 2026

Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

September 24, 2026

Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities

September 23, 2026

Glucotrack Announces $11.5 Million Financing

September 11, 2026

Glucotrack, Inc. Announces Reverse Stock Split

August 27, 2026

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

August 17, 2026

E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack

August 6, 2026

Glucotrack Announces $5.5 Million Financing

August 5, 2026

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

July 31, 2026

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

July 29, 2026

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

July 17, 2026

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

July 16, 2026

Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

July 14, 2026

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

July 8, 2026

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

May 26, 2026

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

May 7, 2026

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

April 30, 2026

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

April 21, 2026

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 29, 2026

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

March 26, 2026

Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit

March 9, 2026

Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

January 29, 2026

Decks in 2026